Search

Background: Cutaneous relapse from endometrial cancer is a rare event, and often is part of a plurimetastatic disease with poor prognosis. Besides palliative chemotherapy, no consensus is present in literature about the specific treatment of skin metastases, in particular in order to improve symptoms. Objectives: In this paper the authors present a case of multi-metastatic endometrial cancer patient with also cutaneous metastasis, treated with palliative systemic therapy and electrochemotherapy. In particular the authors will describe the clinical, dermatoscopic, and pathological features of cutaneous metastases and their management. A literature review on cutaneous metastasis from endometrial cancer is also presented. Materials and Methods: A PubMed research was made using the terms "endometrial carcinoma", "skin", "cutaneous", "metastasis", and "spread". Discussion: The present case of unusual localization of skin metastases from endometrial cancer is the second described in the literature. The other known cases of cutaneous metastasis from endometrial cancer are summarized and reviewed. Electrochemotherapy can be proposed as an effective and safe loco-regional therapy for skin metastases, especially in case of multiple lesions. To the present authors' knowledge this is the first case of cutaneous metastases from endometrial cancer treated with electrochemotherapy.

Endometrial cancer is one of the most frequent female cancers in women. Around 3-14% of endometrial cancers are diagnosed in young women wishing to preserve their fertility. Incidence of endometrial cancer in this age group is increasing, for which fertility-sparing therapy is increasingly need to be used to preserve quality of life in these patients. Progestin-based treatment is the most common type of fertility-sparing therapy. The aim of this review is to assess and analyse most recent findings concerning fertility-sparing progestin therapy for young women with primary and recurrent endometrial cancer. Diagnosis, treatment, follow-up, and oncologic and reproductive outcomes are investigated. Fertility-sparing progestin therapy is highly effective in selected young women with primary and recurrent endometrial cancer. Patients careful selection as to be mandatory to achieve the best outcomes without compromising survival. Because of the not negligible recurrence rate after conservative treatment, close surveillance is required and prophylactic hysterectomy has to be performed in patients completing family planning. Pregnancy outcomes are very encouraging, thanks to assisted reproductive technologies. Medroxyprogesterone acetate and megestrol acetate are the ideal progestins employed for fertility-sparing therapy, but further studies should be made to establish the optimal dose and treatment timing in this setting.

Introduction: Brenner tumor of the ovary represents an uncommon neoplasm. It constitutes about 1.5% of all ovarian tumors with a peak of incidence in the fifth decade. The vast majority of Brenner tumors is benign, while only 1% is malignant and associated with a poor prognosis. Diagnosis could be made only with histological examination, and surgery is the mainstay of treatment. Materials and methods: Here we present the case of a patient affected by a malignant Brenner tumor of the ovary, with metastases to brain, lung and liver and by a concomitant low grade endometroid adenocarcinoma of the uterus. A postoperative platinum based chemotherapy (CHT) was planned. The adjuvant treatment was discontinued for hematologic and liver toxicity and the patient died one month later due to a cardiorespiratory arrest. Results and discussion: For what concerns adjuvant therapy, it is supposed that chemotherapy is profitable in the survival of these patients, but what agents would really provide an objective response in the presence of metastatic disease is not standardized. Conclusion: Because of the rarity and the limited good quality research reports, multicentric prospective trials are needed to improve preoperative diagnosis of MBTs and investigate the best treatment.